Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer

Insights into Imaging

Table 1 Summary data of clinicopathological features of 141 patients

Characteristics	AR + population (n = 102)		AR– population (n = 39)		p value
Characteristics	n	Percent (%)	n	Percent (%)	p value
Age (y)					0.459
Mean ± SD	52.25 ± 11.29		50.72 ± 10.12
Subtype					0.001*
TNBC	4	3.92	18	46.15
Luminal A	36	35.29	6	15.38
Luminal B	31	30.39	4	10.26
HER2 overexpression	31	30.39	11	28.21
Ki-67 (%)					0.027*
< 14	23	22.55	2	5.13
≥ 14	79	77.45	37	94.87
Tumor size (mm)					0.709
Mean ± SD	22.98 ± 14.46		23.95 ± 12.09
Lymph node metastasis					0.361
Absent	61	59.80	19	48.72
Present	41	40.20	20	51.28
Menopausal status					0.624
Non-menopause	45	44.12	19	48.72
Menopause	57	55.88	20	51.28
Distant metastasis					0.695
Absent	96	94.12	36	92.31
Present	6	5.88	3	7.69
Tumor histology					0.099
Invasive ductal carcinoma	82	80.39	36	92.31
Other types	20	19.61	3	7.69
Clinical T stage					0.757
cT1	62	60.78	20	51.28
cT2	29	28.43	17	43.59
cT3 and cT4	11	10.78	2	5.13
Histological grade					0.011*
1	12	11.76	1	2.56
2	50	49.02	15	38.46
3	40	39.22	23	58.97

y, years old; TNBC, triple-negative breast cancer; HER2, human epidermal growth factor receptor 2; AR, androgen receptor; * indicates p < 0.05